{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:59:31Z","timestamp":1785405571384,"version":"3.56.0"},"reference-count":153,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA271533"],"award-info":[{"award-number":["R01CA271533"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA260698"],"award-info":[{"award-number":["R01CA260698"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA275089"],"award-info":[{"award-number":["R01CA275089"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"award":["R01CA271533"],"award-info":[{"award-number":["R01CA271533"]}],"id":[{"id":"https:\/\/ror.org\/045p44t13","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA260698"],"award-info":[{"award-number":["R01CA260698"]}],"id":[{"id":"https:\/\/ror.org\/045p44t13","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA275089"],"award-info":[{"award-number":["R01CA275089"]}],"id":[{"id":"https:\/\/ror.org\/045p44t13","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited effective therapies. Two-dimensional (2D) in vitro models poorly recapitulate tumor microenvironment (TME) interactions, impeding the translational relevance of TNBC immunotherapy research. Three-dimensional patient-derived tumor organoids (3D PDTOs) have emerged as advanced preclinical models that better mimic tumor\u2013immune interactions. The objective of this systematic review was to assess the landscape of 3D PDTO adoption in TNBC research and evaluate their application in addressing key bottlenecks in TNBC immunotherapy. We retrieved 394 studies published between 2015 and 2025 from the PubMed and ClinicalTrials.gov databases. Of those, 153 studies were included in the review. Fifty-eight (58) TNBC-specific studies met the inclusion criteria, including explicit mention of 3D PDTOs in the title or abstract, with confirmation in the Methods and Results sections. Studies were excluded if they used non-patient-derived tumor organoids or referred to other 3D models as 3D PDTOs. Data were collected from January 2025 through December 2025. Eligible studies were screened in three (3) tiers, grouped by relevant themes and graphed in Excel. We present an overview of the adoption of 3D PDTOs in TNBC research, highlighting the most common application trends within this scope. We also discuss the potential impact of artificial intelligence (AI) and regulatory guidance from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pertinent to the adoption of organoids as human-relevant models to improve translational outcomes. Overall, this review provides actionable insights for leveraging 3D PDTOs to advance translational TNBC research and precision oncology.<\/jats:p>","DOI":"10.3390\/cells15100922","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:06:26Z","timestamp":1779696386000},"page":"922","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Organoid Decade: Leveraging 3D Patient-Derived Organoids to Bridge the Translational Gap in Triple-Negative Breast Cancer: A Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3206-9676","authenticated-orcid":false,"given":"Jemima","family":"Sani","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA"},{"name":"Innovations in Drug Discovery (IDD) Program, College of Pharmacy, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaguang","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA"},{"name":"Innovations in Drug Discovery (IDD) Program, College of Pharmacy, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of Triple-Negative Breast Cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"ref_2","unstructured":"American Cancer Society (2024). Breast Cancer Facts and Figures 2024\u20132025, American Cancer Society."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/0008-5472.CAN-21-2807","article-title":"Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics","volume":"82","author":"Bhatia","year":"2022","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14728222.2022.2094762","article-title":"Triple-negative breast cancer drug resistance, durable efficacy, and cure: How advanced biological insights and emerging drug modalities could transform progress","volume":"26","author":"Cirillo","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration (2025, September 23). FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple."},{"key":"ref_6","unstructured":"U.S. Food and Drug Administration (2025, September 23). FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: Modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/cac2.12224","article-title":"Tumor organoids: Synergistic applications, current challenges, and future prospects in cancer therapy","volume":"41","author":"Qu","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41388-022-02586-2","article-title":"Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs","volume":"42","author":"Henriet","year":"2023","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Psilopatis, I., Mantzari, A., Vrettou, K., and Theocharis, S. (2023). The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030773"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12957-023-03231-2","article-title":"Breast cancer organoids and their applications for precision cancer immunotherapy","volume":"21","author":"Guan","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (2025, September 23). Roadmap to Reducing Animal Testing in Preclinical Safety Studies, Available online: https:\/\/www.fda.gov\/files\/newsroom\/published\/roadmap_to_reducing_animal_testing_in_preclinical_safety_studies.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13046-024-03258-7","article-title":"Cancer Organoids as reliable disease models to drive clinical development of novel therapies","volume":"43","author":"Blandino","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12195-020-00625-0","article-title":"Organoids as Complex In Vitro Models for Studying Radiation-Induced Cell Recruitment","volume":"13","author":"Hacker","year":"2020","journal-title":"Cell Mol. Bioeng."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bittman-Soto, X.S., Thomas, E.S., Ganshert, M.E., Mendez-Santacruz, L.L., and Harrell, J.C. (2024). The Transformative Role of 3D Culture Models in Triple-Negative Breast Cancer Research. Cancers, 16.","DOI":"10.3390\/cancers16101859"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e70044","DOI":"10.1002\/ctm2.70044","article-title":"Single-cell transcriptional atlas of human breast cancers and model systems","volume":"14","author":"Altman","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lehmann, B.D., Jovanovi\u0107, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., Moses, H.L., Sanders, M.E., and Pietenpol, J.A. (2016). Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157368"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13058-015-0550-y","article-title":"Gene-expression molecular subtyping of triple-negative breast cancer tumours: Importance of immune response","volume":"17","author":"Loussouarn","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","article-title":"Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets","volume":"33","author":"Gong","year":"2021","journal-title":"Cell Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline Testing in Patients with Breast Cancer: ASCO\u2013Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000538137","article-title":"Functional Precision Medicine Successfully Guides Therapeutic Regimen of \u2018Cancer of Unknown Primary\u2019 Later Classified as Triple-Negative Breast Cancer: A Case Report","volume":"17","author":"Ruhe","year":"2024","journal-title":"Case Rep. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid Modeling of the Tumor Immune Microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1126\/science.25.649.912","article-title":"A New Method by Which Sponges May Be Artificially Reared","volume":"25","author":"Wilson","year":"1907","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"C151","DOI":"10.1152\/ajpcell.00120.2020","article-title":"A brief history of organoids","volume":"319","author":"Novellasdemunt","year":"2020","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1432-0436.1987.tb00183.x","article-title":"Lung organoid culture","volume":"36","author":"Zimmermann","year":"1987","journal-title":"Differentiation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term Expansion of Epithelial Organoids from Human Colon, Adenoma, Adenocarcinoma, and Barrett\u2019s Epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12575-019-0099-8","article-title":"Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer","volume":"21","author":"Mazzucchelli","year":"2019","journal-title":"Biol. Proced. Online"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Campaner, E., Zannini, A., Santorsola, M., Bonazza, D., Bottin, C., Cancila, V., Tripodo, C., Bortul, M., Zanconati, F., and Schoeftner, S. (2020). Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment. Cancers, 12.","DOI":"10.3390\/cancers12123869"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e70023","DOI":"10.1002\/ctm2.70023","article-title":"Distinct discrepancy in breast cancer organoids recapitulation among molecular subtypes revealed by single-cell transcriptomes analysis","volume":"14","author":"Jia","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"104914","DOI":"10.1016\/j.critrevonc.2025.104914","article-title":"Breast cancer organoids: Advancements and applications in precision medicine","volume":"214","author":"Leung","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2204097","DOI":"10.1002\/advs.202204097","article-title":"Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy","volume":"9","author":"Mo","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.gie.2024.04.012","article-title":"EUS-guided biopsies versus surgical specimens for establishing patient-derived pancreatic cancer organoids: A systematic review and meta-analysis","volume":"100","author":"Sodal","year":"2024","journal-title":"Gastrointest. Endosc."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhou, L., Zhang, C., Zhang, Y., and Shi, C. (2021). Application of Organoid Models in Prostate Cancer Research. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.736431"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100903","DOI":"10.1016\/j.drup.2022.100903","article-title":"A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24\u2212 enriched breast cancer stem-like cells","volume":"66","author":"Liu","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Stoppini, L., Heuschkel, M.O., Loussert-Fonta, C., Gomez Baisac, L., and Roux, A. (2024). Versatile micro-electrode array to monitor human iPSC-derived 3D neural tissues at air-liquid interface. Front. Cell. Neurosci., 18.","DOI":"10.3389\/fncel.2024.1389580"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"R44","DOI":"10.1530\/VB-22-0001","article-title":"Angiorganoid: Vitalizing the organoid with blood vessels","volume":"4","author":"Ma","year":"2022","journal-title":"Vasc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41388-023-02858-5","article-title":"KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer","volume":"42","author":"Yao","year":"2023","journal-title":"Oncogene"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eadf1128","DOI":"10.1126\/scitranslmed.adf1128","article-title":"Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer","volume":"15","author":"Xu","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-022-01345-w","article-title":"CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer","volume":"18","author":"Wu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.chembiol.2024.06.012","article-title":"A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer","volume":"31","author":"Cetin","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hou, Y., Hao, H., Yuan, Y., Zhang, J., Liu, Z., Nie, Y., Zhang, S., Yuan, S., and Yang, M. (2024). Nifuratel Induces Triple-Negative Breast Cancer Cell G2\/M Phase Block and Apoptosis by Regulating GADD45A. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101269"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12935-024-03313-5","article-title":"Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: Exploring chidamide and enzalutamide as a promising combination strategy","volume":"24","author":"Zhao","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e2207201119","DOI":"10.1073\/pnas.2207201119","article-title":"Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression","volume":"119","author":"Yang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-024-07502-8","article-title":"BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors","volume":"209","author":"Hench","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11626-021-00563-9","article-title":"Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform","volume":"57","author":"Pan","year":"2021","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Granit Mizrahi, A., Gugenheim, A., Hamad, H., Hamed, R., Tetro, N., Maimon, O., Khutsurauli, S., Nechushtan, H., Nisman, B., and Duran, D. (2023). Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1217149"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e181368","DOI":"10.1172\/JCI181368","article-title":"Neuropilin-2-expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling","volume":"134","author":"Kumar","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1021\/acs.jmedchem.2c01682","article-title":"Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells","volume":"66","author":"He","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"eadj1564","DOI":"10.1126\/sciadv.adj1564","article-title":"A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells","volume":"10","author":"Bulanova","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e2316615121","DOI":"10.1073\/pnas.2316615121","article-title":"Iridium(III) carbene complexes as potent girdin inhibitors against metastatic cancers","volume":"121","author":"Ruan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1016\/j.cell.2025.09.001","article-title":"Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens","volume":"188","author":"Zhou","year":"2025","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2303088","DOI":"10.1002\/advs.202303088","article-title":"Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy","volume":"11","author":"Choi","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Hetzel, L.A., Ali, A., Corbo, V., and Hankemeier, T. (2023). Microfluidics and Organoids, the Power Couple of Developmental Biology and Oncology Studies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310882"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.stem.2022.04.006","article-title":"Patient-derived micro-organospheres enable clinical precision oncology","volume":"29","author":"Ding","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1039\/D1LC00689D","article-title":"Microfluidic organ-on-chip system for multi-analyte monitoring of metabolites in 3D cell cultures","volume":"22","author":"Dornhof","year":"2022","journal-title":"Lab. Chip"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e2207257","DOI":"10.1002\/advs.202207257","article-title":"Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy","volume":"10","author":"Jiang","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-21-1299","article-title":"DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer","volume":"28","author":"Kurani","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-023-01806-x","article-title":"A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer","volume":"22","author":"Song","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/1878-0261.13209","article-title":"Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: Potential for drug repositioning as an anti-tumor agent","volume":"16","author":"Jung","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"216142","DOI":"10.1016\/j.canlet.2023.216142","article-title":"Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF\u03b2 signaling pathway","volume":"560","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2305035","DOI":"10.1002\/advs.202305035","article-title":"Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple-Negative Breast Cancer","volume":"11","author":"Zhong","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Divoux, J., Florent, R., Jacobs, M., Lequesne, J., Grellard, J.-M., San, C., Grossi, S., Kerdja, K., Clarisse, B., and Boudier, G. (2023). The TRIPLEX study: Use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11362-8"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1158\/0008-5472.CAN-24-0970","article-title":"Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer","volume":"84","author":"Hillis","year":"2024","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"110567","DOI":"10.1016\/j.cbi.2023.110567","article-title":"Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer","volume":"382","author":"Gong","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3892\/or.2021.8205","article-title":"Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines","volume":"46","author":"Thongchot","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.7150\/thno.97662","article-title":"TRIM4 enhances small-molecule-induced neddylated-degradation of CORO1A for triple negative breast cancer therapy","volume":"14","author":"Gu","year":"2024","journal-title":"Theranostics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13058-024-01788-8","article-title":"Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers","volume":"26","author":"Derouane","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11843","DOI":"10.1038\/s41598-023-37058-4","article-title":"Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy","volume":"13","author":"Dong","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1172\/JCI97924","article-title":"DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine","volume":"128","author":"Yu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"zcaa039","DOI":"10.1093\/narcan\/zcaa039","article-title":"CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer","volume":"2","author":"Cairns","year":"2020","journal-title":"NAR Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.7150\/jca.94822","article-title":"Stigmasterol Attenuates Triple-negative Breast Cancer Stem Cell Properties by Inhibiting JAK3","volume":"16","author":"Zhou","year":"2025","journal-title":"J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e70203","DOI":"10.1002\/ctm2.70203","article-title":"RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic-nuclear shuttling in human triple-negative breast cancer","volume":"15","author":"Huang","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/s41416-024-02591-0","article-title":"Antibodies toward Na+,HCO3\u2212-cotransporter NBCn1\/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer","volume":"130","author":"Axelsen","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2405257121","DOI":"10.1073\/pnas.2405257121","article-title":"An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche","volume":"121","author":"Baldassarri","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13046-025-03355-1","article-title":"CircPVT1 weakens miR-33a-5p unleashing the c-MYC\/GLS1 metabolic axis in breast cancer","volume":"44","author":"Palcau","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"RP95106","DOI":"10.7554\/eLife.95106","article-title":"Telomere length sensitive regulation of interleukin receptor 1 type 1 (IL1R1) by the shelterin protein TRF2 modulates immune signalling in the tumour microenvironment","volume":"13","author":"Mukherjee","year":"2024","journal-title":"eLife"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e06253","DOI":"10.1002\/advs.202506253","article-title":"Serine\/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple-Negative Breast Cancer","volume":"12","author":"Jiang","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Rao, X., Qiao, Z., Yang, Y., Deng, Y., Zhang, Z., Yu, X., and Guo, X. (2024). Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening. Pharmaceuticals, 17.","DOI":"10.3390\/ph17020225"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1038\/s41388-021-01655-2","article-title":"Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor","volume":"40","author":"Ge","year":"2021","journal-title":"Oncogene"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13058-021-01461-4","article-title":"Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models","volume":"23","author":"Chew","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","article-title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer","volume":"11","author":"Saatci","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.breast.2021.03.011","article-title":"Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer","volume":"58","author":"Parsyan","year":"2021","journal-title":"Breast"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sharick, J.T., Walsh, C.M., Sprackling, C.M., Pasch, C.A., Pham, D.L., Esbona, K., Choudhary, A., Garcia-Valera, R., Burkard, M.E., and McGregor, S.M. (2020). Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00553"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Yousafzai, N.A., El Khalki, L., Wang, W., Szpendyk, J., and Sossey-Alaoui, K. (2024). Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16050883"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1158\/1541-7786.MCR-19-0453","article-title":"Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response","volume":"18","author":"Kim","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"103775","DOI":"10.1016\/j.redox.2025.103775","article-title":"PNKP targeting engages the autophagic machinery through STING and STAT3 to potentiate ferroptosis and chemotherapy in TNBC","volume":"86","author":"Maimon","year":"2025","journal-title":"Redox Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13014-024-02410-z","article-title":"PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer","volume":"19","author":"Pellizzari","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Randolph, L., Joshi, J., Rodriguez Sanchez, A.L., Pratap, U.P., Gopalam, R., Chen, Y., Lai, Z., Santhamma, B., Kost, E.R., and Nair, H.B. (2024). Significance of LIF\/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16213630"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1038\/s41598-024-53843-1","article-title":"Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage","volume":"14","author":"Wu","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"122883","DOI":"10.1016\/j.biomaterials.2024.122883","article-title":"Mitochondrial-uncoupling nanomedicine for self-heating and immunometabolism regulation in cancer cells","volume":"314","author":"Yang","year":"2025","journal-title":"Biomaterials"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zou, J., Shah, O., Chiu, Y.C., Ma, T., Atkinson, J.M., Oesterreich, S., Lee, A.V., and Tseng, G.C. (2024). Systems approach for congruence and selection of cancer models towards precision medicine. PLoS Comput. Biol., 20.","DOI":"10.1371\/journal.pcbi.1011754"},{"key":"ref_101","unstructured":"University of Utah (2026, April 03). Towards Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple Negative Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05464082."},{"key":"ref_102","unstructured":"University Health Network, Toronto (2026, April 03). Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02732860."},{"key":"ref_103","unstructured":"Istituti Clinici Scientifici Maugeri SpA (2026, April 03). Prospective Multicenter Study on the Collection of Tumor Biopsies and the Generation of Organoids Derived from Breast Cancer Patients Scheduled for Neoadjuvant Chemotherapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07260188."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","article-title":"Comprehensive metabolomics expands precision medicine for triple-negative breast cancer","volume":"32","author":"Xiao","year":"2022","journal-title":"Cell Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"znad408","DOI":"10.1093\/bjs\/znad408","article-title":"Patient-derived organoids for prediction of treatment response in oesophageal adenocarcinoma","volume":"111","author":"Bolger","year":"2024","journal-title":"Br. J. Surg."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"114751","DOI":"10.1016\/j.biopha.2023.114751","article-title":"Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing","volume":"163","author":"Zu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SLA.0000000000005558","article-title":"Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy","volume":"276","author":"Demyan","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-21-0982","article-title":"Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study","volume":"27","author":"Forsythe","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.medj.2021.08.005","article-title":"Promises and Challenges of Organoid-Guided Precision Medicine","volume":"2","author":"Bose","year":"2021","journal-title":"Med"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/jgh.15930","article-title":"Patient-derived cancer organoids for drug screening: Basic technology and clinical application","volume":"37","author":"Ren","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"295","DOI":"10.15283\/ijsc20082","article-title":"The Progress and Clinical Application of Breast Cancer Organoids","volume":"13","author":"Yu","year":"2020","journal-title":"Int. J. Stem Cells"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15330338241285097","DOI":"10.1177\/15330338241285097","article-title":"Development of Liver Cancer Organoids: Reproducing Tumor Microenvironment and Advancing Research for Liver Cancer Treatment","volume":"23","author":"Li","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","article-title":"Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation","volume":"130","author":"Viergever","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_117","unstructured":"(2025, September 24). Roche Provides Update on Tecentriq US Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2021-08-27."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/1871520621666210618100857","article-title":"Single-Cell Transcriptome Analysis Reveals the M2 Macrophages and Exhausted T Cells and Intratumoral Heterogeneity in Triple-Negative Breast Cancer","volume":"22","author":"Xu","year":"2022","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.crmeth.2024.100792","article-title":"A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses","volume":"4","author":"Hajjaji","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"127639","DOI":"10.1016\/j.ijbiomac.2023.127639","article-title":"SILAC proteomics based on 3D cell spheroids unveils the role of RAC2 in regulating the crosstalk between triple-negative breast cancer cells and tumor-associated macrophages","volume":"254","author":"Guo","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.14440\/jbm.2016.132","article-title":"A three-dimensional co-culture system to investigate macrophage-dependent tumor cell invasion","volume":"3","author":"Dwyer","year":"2016","journal-title":"J. Biol. Methods"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-23-0641","article-title":"Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress","volume":"14","author":"Zhao","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"20240674","DOI":"10.1098\/rsif.2024.0674","article-title":"Scientific hypothesis generation by large language models: Laboratory validation in breast cancer treatment","volume":"22","author":"Zenil","year":"2025","journal-title":"J. R. Soc. Interface"},{"key":"ref_124","unstructured":"U.S. Food and Drug Administration (2026, April 04). General Considerations for the Use of New Approach Methodologies in Drug Development, Available online: https:\/\/www.fda.gov\/media\/191589\/download."},{"key":"ref_125","unstructured":"U.S. Food and Drug Administration (2025, December 22). Alternative Methods Publications and Events, Available online: https:\/\/www.fda.gov\/science-research\/advancing-alternative-methods-fda\/alternative-methods-publications-and-events."},{"key":"ref_126","unstructured":"U.S. Food and Drug Administration (2025, December 22). FDA\u2019s Alternative Methods Forum Series, Available online: https:\/\/www.fda.gov\/science-research\/advancing-alternative-methods-fda\/fdas-alternative-methods-forum-series."},{"key":"ref_127","unstructured":"U.S. Food and Drug Administration (2025, December 22). CDER\/Office of New Drugs Streamlined Nonclinical Studies and Acceptable New Approach Methodologies (NAMs), Available online: https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/cderoffice-new-drugs-streamlined-nonclinical-studies-and-acceptable-new-approach-methodologies-nams."},{"key":"ref_128","unstructured":"United States Congress (2025, December 22). S.5002\u2014FDA Modernization Act 2.0, Available online: https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/5002."},{"key":"ref_129","unstructured":"U.S. Food and Drug Administration (2025, December 22). FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs."},{"key":"ref_130","unstructured":"National Institutes of Health (2025, December 22). NIH Standardized Organoid Modeling (SOM) Center, Available online: https:\/\/www.nih.gov\/som."},{"key":"ref_131","unstructured":"European Medicines Agency (2025, June 07). EMA Regulatory Science to 2025. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf."},{"key":"ref_132","unstructured":"European Medicines Agency (2025, June 07). New Approach Methodologies. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/report\/new-approach-methodologies-eu-horizon-scanning-report_en.pdf."},{"key":"ref_133","unstructured":"European Medicines Agency (2025, June 07). Artificial Intelligence Workplan to Guide Use of AI in Medicines Regulation. Available online: https:\/\/www.ema.europa.eu\/en\/news\/artificial-intelligence-workplan-guide-use-ai-medicines-regulation."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"104614","DOI":"10.1016\/j.ebiom.2023.104614","article-title":"Patient-derived melanoma organoid models facilitate the assessment of immunotherapies","volume":"92","author":"Ou","year":"2023","journal-title":"EBioMedicine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00262-016-1927-1","article-title":"A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents","volume":"66","author":"Herter","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-019-0553-9","article-title":"Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA\/B and NKG2A targeting for cancer treatment","volume":"7","author":"Courau","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"ref_139","unstructured":"(2026, April 18). ChristianaCare Launches Organoid Core to Personalize Cancer Treatment. Available online: https:\/\/news.christianacare.org\/2025\/11\/christianacare-launches-organoid-core-to-personalize-cancer-treatment\/."},{"key":"ref_140","unstructured":"Wake Forest University School of Medicine (2026, April 18). Organoid Pathology Lab. Available online: https:\/\/school.wakehealth.edu\/research\/institutes-and-centers\/comprehensive-cancer-center\/shared-resources-and-cores\/tumor-tissue-and-pathology\/organoid-pathology-lab."},{"key":"ref_141","unstructured":"Wake Forest University School of Medicine (2026, April 18). WFORCE\u2014Wake Forest Organoid Research Center. Available online: https:\/\/school.wakehealth.edu\/research\/institutes-and-centers\/wake-forest-institute-for-regenerative-medicine\/research\/wforce."},{"key":"ref_142","unstructured":"(2026, April 18). Cure First. Cure First. Available online: https:\/\/cure-first.org\/."},{"key":"ref_143","unstructured":"(2026, April 18). Predicting Drug Response in MicroOrganoSpheres\u00ae Using Brightfield Images. Available online: https:\/\/xilis.com\/predicting-drug-response-in-microorganospheres-using-brightfield-images\/."},{"key":"ref_144","unstructured":"(2026, April 18). Hub Organoids. A Patient in the Lab. Available online: https:\/\/huborganoids.nl\/wp-content\/uploads\/2022\/02\/Flyer-HUB-Toxicology-Organoid-Models.pdf."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"102226","DOI":"10.1016\/j.tranon.2024.102226","article-title":"Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy","volume":"51","author":"Taurin","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41746-025-01967-7","article-title":"Machine learning analysis reveals tumor heterogeneity and stromal-immune niches in breast cancer","volume":"8","author":"Kuang","year":"2025","journal-title":"npj Digit. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/jamia\/ocae291","article-title":"Using human factors methods to mitigate bias in artificial intelligence-based clinical decision support","volume":"32","author":"Militello","year":"2025","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e253172","DOI":"10.1001\/jamahealthforum.2025.3172","article-title":"Early Recalls and Clinical Validation Gaps in Artificial Intelligence-Enabled Medical Devices","volume":"6","author":"Lee","year":"2025","journal-title":"JAMA Health Forum"},{"key":"ref_149","unstructured":"U.S. Food and Drug Administration (2025, November 13). Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"20220878","DOI":"10.1259\/bjr.20220878","article-title":"Data drift in medical machine learning: Implications and potential remedies","volume":"96","author":"Sahiner","year":"2023","journal-title":"Br. J. Radiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41746-024-01275-6","article-title":"A data-driven framework for identifying patient subgroups on which an AI\/machine learning model may underperform","volume":"7","author":"Subbaswamy","year":"2024","journal-title":"npj Digit. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"101372","DOI":"10.1016\/j.isci.2020.101372","article-title":"Spatiotemporal Gradient and Instability of Wnt Induce Heterogeneous Growth and Differentiation of Human Intestinal Organoids","volume":"23","author":"Shin","year":"2020","journal-title":"iScience"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-18-3590","article-title":"Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation","volume":"25","author":"Pasch","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/10\/922\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:29:31Z","timestamp":1779769771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/10\/922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":153,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cells15100922"],"URL":"https:\/\/doi.org\/10.3390\/cells15100922","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}